Ecolab 2026 Growth Drivers for High-Tech and Life Sciences Segments

Thermo Fisher’s revenue growth outlook for Q1 2026

In the earnings call covering Q1 2026, Thermo Fisher reported Q1 2026 revenue growth of 6% year-over-year to $11.01 billion.¹ The company also broke out the drivers of reported revenue growth as ~1% organic, ~3% from acquisitions, and ~2% from foreign exchange.²

Because the question asks for the revenue growth outlook for Q1 2026, the most direct “outlook” guidance/benchmarking language in the excerpts is that Q1 end markets were “progressing as expected” in line with original guidance.¹ On the organic side, Thermo Fisher stated that its full-year guidance continues to assume 3% to 4% organic revenue growth (this frames the overall “expected” revenue growth trajectory, including Q1 vs later quarters).³ It further explained that the reported 1% organic growth in Q1 was affected by one fewer selling day (about 1 percentage point impact).²

What that implies about Q1 organic growth conditions

• Q1 reported revenue grew 6% YoY.¹
• Q1 organic growth was ~1% (with the company attributing that to 1 point selling-day impact).²
• Segment color also supports weaker organic momentum in parts of the portfolio: Analytical Instruments had organic revenue down 2% YoY, and Specialty Diagnostics had organic revenue down 3% YoY.⁴

So, while management described Q1 performance as on-track versus expectations,¹ the internal drivers indicate Q1 organic growth was modest, with weakness tied to specific demand and calendar/timing factors.⁴²

---

How Q1 2026 performance influences full-year guidance

Thermo Fisher explicitly linked its full-year revenue guidance raise to the “strong start” and acquisition activity:

• Management said it is raising its 2026 full-year guide to reflect the strong start to the year and the acquisition of Clario.³⁵
• The company raised full-year revenue guidance to $47.3 billion–$48.1 billion, which implies 6%–8% reported revenue growth over 2025.⁶

The organic growth assumption is unchanged at the full-year level

Even after raising total revenue, Thermo Fisher stated its updated full-year guidance continues to assume 3% to 4% organic revenue growth.³⁶ The company also reiterated that at the midpoint, organic growth is slightly above 3%.³

Clario is the main incremental reason the total revenue guide is higher

Thermo Fisher’s excerpts specify that the guidance increase incorporates the acquisition:

• The increase in 2026 revenue guidance includes $900 million higher revenue from Clario.³
• Management said the acquisition increased 2026 revenue guidance by $900 million.³
• For context on how Clario affected Q1 (and signals deal integration), the CFO noted Clario added $30 million of revenue and $0.01 of adjusted EPS to Q1 2026 results and is on track with integration progressing well.⁷

Foreign exchange tailwind is also explicitly embedded

The full-year guidance still assumes FX benefits:

• Thermo Fisher continues to assume a $300 million tailwind to revenue from foreign exchange for the year.³

“Strong Q1 operational performance” offsets other pressures, but does not change the organic growth range

The company’s narrative indicates the full-year raise is a net result of strong execution plus acquisition contribution, partially offset by macro/headwind assumptions:

• At the midpoint, management described the guidance includes $900 million higher revenue and added margin expansion and adjusted EPS increases driven by Clario and “strong operational performance in Q1,” while also including an assumption for higher inflation in future quarters that management is actively working to mitigate.³
• Management also highlighted macro/inflation complexity and assumed customer end markets remain resilient.⁸

---

Bottom line

• Q1 2026 revenue growth outcome: +6% YoY to $11.01B,¹ driven by ~1% organic,² ~3% from acquisitions (including Clario),² and ~2% from FX.² Organic performance in some key segments was negative (Analytical Instruments -2%, Specialty Diagnostics -3%), consistent with the modest total organic growth.⁴
• Impact on full-year guidance: Thermo Fisher raised full-year revenue guidance to $47.3B–$48.1B (implying 6%–8% reported growth), explicitly attributing the raise to the strong start in Q1 plus the Clario acquisition.³⁶
• Organic outlook for the year: Despite the raise, management kept the full-year organic revenue growth assumption at 3%–4%, meaning Q1 strength influenced total revenue/earnings mainly through execution and acquisition integration rather than by increasing the organic growth target.³⁶